InVitro Diagnostics (IVD) Market, 2012 to 2023
Invitro diagnostics market: Invitro diagnostics are used to detect infectious diseases, and also used to monitor the health status of a person and therapeutic procedures by examining the specimens like blood, tissue, urine, stools and other bodily fluids. Various technologies are incorporated in in-vitro diagnostics such as microarray techniques, mass spectrometry, polymerase chain reaction and sequencing technology are used for testing the sample preparation.
Market Outline: Global In Vitro Diagnostics Market
Increasing expenditure on healthcare sector in emerging markets, huge demand for novel diagnostic methods for diagnosis of the diseases are expected to create demand for in vitro diagnostics. Rising adaptation of point care testing, rising incidences of lifestyle diseases are expected to boost the market. As per 2014 report of National Diabetes Statistics states that about 9.3% of U.S. population have diabetes and about 8.1Mn people are undiagnosed, In accordance with WHO, about 5Mn deaths were recorded because of the chronic diseases like TB, Malaria, and AIDS in 2011, around 8.7 Mn cases registered due to TB. Cancer accounted for 7.9Mn deaths and anticipated to reach 11Mn by 2030. Increase in the number of laboratories with sophisticated infrastructure in developed countries is the few factors expected to boost the growth of Invitro diagnostics market. However, unfavourable reimbursement policies in developing countries and strict regulatory framework are few factors that are restraining the growth of the IVD market.
The InVitro Diagnostics (IVD) market is classified on the basis of product type, application, techniques, end user and geography.
Based on product type, Invitro diagnostics market is segmented into the following
Reagents and consumables
Instruments
Based on techniques, Invitro diagnostics market is segmented into the following
Immunochemistry
Molecular diagnostics
Clinical chemistry
Tissue diagnostics
Hemostasis and Coagulation
Others
Based on Application, Invitro diagnostics (IVD) market is segmented into the following
Cancer
Infectious diseases
Nephrological diseases
Immune system disorders
Gastrointestinal disorders
Neurological disorders
Hematological disorders
Others
Based on end user, Invitro diagnostics market is segmented into the following
Hospitals
Diagnostic Centres
Point-of-care testing
Others
Players in Invitro diagnostics are focusing on acquisitions, exclusive agreements and strategic collaborations in order to expand their business. In February 2015, Roche has acquired Signature Diagnostics to strengthen its cancer diagnostics. In February 2014, Thermo Fisher Scientific has acquired Life Technologies Corporation to strengthen it’s of next-generation sequencing space segment. Different organizations are being operated in order to monitor the industry. For example, BIVDA (British In Vitro Diagnostics Association) is an association of various companies in the UK which represents the manufacturers and distributors with high interest and involvement. Recently, Life Technology Corporation in Europe has launched CE-IVD Marked QuantStudio Dx Real-Time PCR instrument.
On the basis of geographical regions, is Invitro diagnostics market classified as into five key regions as Europe, Asia- Pacific, North America, Europe, Middle East & Africa and Latin America. North America is the largest market with the highest share of the IVD market, which is followed by the Europe owing easy accessibility for advanced technologies, the presence of the large pool of manufacturers in IVD market, increasing the prevalence of chronic genetic and lifestyle diseases. Asia-Pacific is expected to show fastest growth rate and also will emerge as the area with maximum growth potential owing to the improving infrastructure of the healthcare sector and growing economies in India and China.
The key players in this market are Becton, Dickinson and Company (U.S.), Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (U.S.), Sysmex Corporation (Japan), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Qiagen N.V. (Germany), Diasorin S.P.A. (Italy).Ortho-Clinical Diagnostics, Inc. (U.S.), and Johnson and Johnson (U.S.).
In 2015 April, Abbott and Sekisui entered into an agreement for providing solutions of coagulation testing for laboratories across the world.
In 2014 December, Roche expanded its CE-IVD for testing of human organ and tissue for next-gen blood screening assays. cobas MPX and Cobas WNV assays can be used to test tissue and human organ, therefore expanding the range of approved uses for the cobas 6800/8800 systems and assays.
Market Outline: Global In Vitro Diagnostics Market
Increasing expenditure on healthcare sector in emerging markets, huge demand for novel diagnostic methods for diagnosis of the diseases are expected to create demand for in vitro diagnostics. Rising adaptation of point care testing, rising incidences of lifestyle diseases are expected to boost the market. As per 2014 report of National Diabetes Statistics states that about 9.3% of U.S. population have diabetes and about 8.1Mn people are undiagnosed, In accordance with WHO, about 5Mn deaths were recorded because of the chronic diseases like TB, Malaria, and AIDS in 2011, around 8.7 Mn cases registered due to TB. Cancer accounted for 7.9Mn deaths and anticipated to reach 11Mn by 2030. Increase in the number of laboratories with sophisticated infrastructure in developed countries is the few factors expected to boost the growth of Invitro diagnostics market. However, unfavourable reimbursement policies in developing countries and strict regulatory framework are few factors that are restraining the growth of the IVD market.
The InVitro Diagnostics (IVD) market is classified on the basis of product type, application, techniques, end user and geography.
Based on product type, Invitro diagnostics market is segmented into the following
Reagents and consumables
Instruments
Based on techniques, Invitro diagnostics market is segmented into the following
Immunochemistry
Molecular diagnostics
Clinical chemistry
Tissue diagnostics
Hemostasis and Coagulation
Others
Based on Application, Invitro diagnostics (IVD) market is segmented into the following
Cancer
Infectious diseases
Nephrological diseases
Immune system disorders
Gastrointestinal disorders
Neurological disorders
Hematological disorders
Others
Based on end user, Invitro diagnostics market is segmented into the following
Hospitals
Diagnostic Centres
Point-of-care testing
Others
Players in Invitro diagnostics are focusing on acquisitions, exclusive agreements and strategic collaborations in order to expand their business. In February 2015, Roche has acquired Signature Diagnostics to strengthen its cancer diagnostics. In February 2014, Thermo Fisher Scientific has acquired Life Technologies Corporation to strengthen it’s of next-generation sequencing space segment. Different organizations are being operated in order to monitor the industry. For example, BIVDA (British In Vitro Diagnostics Association) is an association of various companies in the UK which represents the manufacturers and distributors with high interest and involvement. Recently, Life Technology Corporation in Europe has launched CE-IVD Marked QuantStudio Dx Real-Time PCR instrument.
On the basis of geographical regions, is Invitro diagnostics market classified as into five key regions as Europe, Asia- Pacific, North America, Europe, Middle East & Africa and Latin America. North America is the largest market with the highest share of the IVD market, which is followed by the Europe owing easy accessibility for advanced technologies, the presence of the large pool of manufacturers in IVD market, increasing the prevalence of chronic genetic and lifestyle diseases. Asia-Pacific is expected to show fastest growth rate and also will emerge as the area with maximum growth potential owing to the improving infrastructure of the healthcare sector and growing economies in India and China.
The key players in this market are Becton, Dickinson and Company (U.S.), Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (U.S.), Sysmex Corporation (Japan), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Qiagen N.V. (Germany), Diasorin S.P.A. (Italy).Ortho-Clinical Diagnostics, Inc. (U.S.), and Johnson and Johnson (U.S.).
In 2015 April, Abbott and Sekisui entered into an agreement for providing solutions of coagulation testing for laboratories across the world.
In 2014 December, Roche expanded its CE-IVD for testing of human organ and tissue for next-gen blood screening assays. cobas MPX and Cobas WNV assays can be used to test tissue and human organ, therefore expanding the range of approved uses for the cobas 6800/8800 systems and assays.
1. EXECUTIVE SUMMARY
2. GLOBAL INVITRO DIAGNOSTICS MARKET INTRODUCTION
2.1. Global Invitro Diagnostics Market – Taxonomy
2.2. Global Invitro Diagnostics Market –Definitions
2.2.1. Product
2.2.2. Technique
2.2.3. Application
2.2.4. End-User
3. GLOBAL INVITRO DIAGNOSTICS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Invitro Diagnostics Market Dynamics – Factors Impact Analysis
3.6. Global Invitro Diagnostics Market – Regulations
3.6.1. U.S.
3.6.2. Europe
4. GLOBAL INVITRO DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL INVITRO DIAGNOSTICS MARKET , BY PRODUCT, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Reagents and consumables
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Instruments
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6. GLOBAL INVITRO DIAGNOSTICS MARKET FORECAST, BY TECHNIQUE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Immunochemistry
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Molecular diagnostics
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Clinical chemistry
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Tissue diagnostics
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Hemostasis and Coagulation
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Others
6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
7. GLOBAL INVITRO DIAGNOSTICS MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Cancer
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Infectious diseases
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Nephrological diseases
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Immune system disorders
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Gastrointestinal disorders
7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Neurological disorders
7.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.6.3. Market Opportunity Analysis
7.7. Hematological disorders
7.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.7.3. Market Opportunity Analysis
7.8. Others
7.8.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.8.3. Market Opportunity Analysis
8. GLOBAL INVITRO DIAGNOSTICS MARKET FORECAST, BY END-USER, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Hospitals
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Diagnostic Centres
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Point-of-care testing
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Others
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
9. GLOBAL INVITRO DIAGNOSTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. North America
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Invitro Diagnostics Market - Opportunity Analysis Index, By Product, By Technique, By Application, By End-User, and Region, 2017 – 2023
10. NORTH AMERICA INVITRO DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Reagents and consumables
10.1.2. Instruments
10.2. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Immunochemistry
10.2.2. Molecular diagnostics
10.2.3. Clinical chemistry
10.2.4. Tissue diagnostics
10.2.5. Hemostasis and Coagulation
10.2.6. Others
10.3. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Cancer
10.3.2. Infectious diseases
10.3.3. Nephrological diseases
10.3.4. Immune system disorders
10.3.5. Gastrointestinal disorders
10.3.6. Neurological disorders
10.3.7. Hematological disorders
10.3.8. Others
10.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospitals
10.4.2. Diagnostic Centres
10.4.3. Point-of-care testing
10.4.4. Others
10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Invitro Diagnostics Market - Opportunity Analysis Index, By Product, By Technique, By Application, By End-User, and Country, 2017 – 2023
10.7. North America Invitro Diagnostics Market Dynamics – Trends
11. EUROPE INVITRO DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Reagents and consumables
11.1.2. Instruments
11.2. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Immunochemistry
11.2.2. Molecular diagnostics
11.2.3. Clinical chemistry
11.2.4. Tissue diagnostics
11.2.5. Hemostasis and Coagulation
11.2.6. Others
11.3. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Cancer
11.3.2. Infectious diseases
11.3.3. Nephrological diseases
11.3.4. Immune system disorders
11.3.5. Gastrointestinal disorders
11.3.6. Neurological disorders
11.3.7. Hematological disorders
11.3.8. Others
11.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospitals
11.4.2. Diagnostic Centres
11.4.3. Point-of-care testing
11.4.4. Others
11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Invitro Diagnostics Market - Opportunity Analysis Index, By Product, By Technique, By Application, By End-User, and Country, 2017 – 2023
11.7. Europe Invitro Diagnostics Market Dynamics – Trends
12. ASIA-PACIFIC INVITRO DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Reagents and consumables
12.1.2. Instruments
12.2. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Immunochemistry
12.2.2. Molecular diagnostics
12.2.3. Clinical chemistry
12.2.4. Tissue diagnostics
12.2.5. Hemostasis and Coagulation
12.2.6. Others
12.3. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Cancer
12.3.2. Infectious diseases
12.3.3. Nephrological diseases
12.3.4. Immune system disorders
12.3.5. Gastrointestinal disorders
12.3.6. Neurological disorders
12.3.7. Hematological disorders
12.3.8. Others
12.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospitals
12.4.2. Diagnostic Centres
12.4.3. Point-of-care testing
12.4.4. Others
12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Invitro Diagnostics Market - Opportunity Analysis Index, By Product, By Technique, By Application, By End-User, and Country, 2017 – 2023
12.7. Asia- Pacific Invitro Diagnostics Market Dynamics – Trends
13. LATIN AMERICA INVITRO DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Reagents and consumables
13.1.2. Instruments
13.2. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Immunochemistry
13.2.2. Molecular diagnostics
13.2.3. Clinical chemistry
13.2.4. Tissue diagnostics
13.2.5. Hemostasis and Coagulation
13.2.6. Others
13.3. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Cancer
13.3.2. Infectious diseases
13.3.3. Nephrological diseases
13.3.4. Immune system disorders
13.3.5. Gastrointestinal disorders
13.3.6. Neurological disorders
13.3.7. Hematological disorders
13.3.8. Others
13.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospitals
13.4.2. Diagnostic Centres
13.4.3. Point-of-care testing
13.4.4. Others
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Venezuela
13.5.5. Rest of Latin America
13.6. Latin America Invitro Diagnostics Market - Opportunity Analysis Index, By Product, By Technique, By Application, By End-User, and Country, 2017 – 2023
13.7. Latin America Invitro Diagnostics Market Dynamics – Trends
14. MIDDLE EAST AND AFRICA INVITRO DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
14.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Reagents and consumables
14.1.2. Instruments
14.2. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Immunochemistry
14.2.2. Molecular diagnostics
14.2.3. Clinical chemistry
14.2.4. Tissue diagnostics
14.2.5. Hemostasis and Coagulation
14.2.6. Others
14.3. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Cancer
14.3.2. Infectious diseases
14.3.3. Nephrological diseases
14.3.4. Immune system disorders
14.3.5. Gastrointestinal disorders
14.3.6. Neurological disorders
14.3.7. Hematological disorders
14.3.8. Others
14.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospitals
14.4.2. Diagnostic Centres
14.4.3. Point-of-care testing
14.4.4. Others
14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Invitro Diagnostics Market - Opportunity Analysis Index, By Product, By Technique, By Application, By End-User, and Country, 2017 – 2023
14.7. MEA Invitro Diagnostics Market Dynamics – Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Becton, Dickinson and Company (U.S.)
15.2.2. Abbott Laboratories (U.S.)
15.2.3. Danaher Corporation (U.S.)
15.2.4. Roche Diagnostics (Switzerland)
15.2.5. Siemens Healthineers (Germany)
15.2.6. Thermo Fisher Scientific, Inc. (U.S.)
15.2.7. Sysmex Corporation (Japan)
15.2.8. bioMérieux (France)
15.2.9. Bio-Rad Laboratories, Inc. (U.S.)
15.2.10. Qiagen N.V. (Germany)
15.2.11. Diasorin S.P.A. (Italy)
15.2.12. Ortho-Clinical Diagnostics, Inc. (U.S.)
15.2.13. Johnson and Johnson (U.S.)
16. RESEARCH METHODOLOGY
17. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL INVITRO DIAGNOSTICS MARKET INTRODUCTION
2.1. Global Invitro Diagnostics Market – Taxonomy
2.2. Global Invitro Diagnostics Market –Definitions
2.2.1. Product
2.2.2. Technique
2.2.3. Application
2.2.4. End-User
3. GLOBAL INVITRO DIAGNOSTICS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Invitro Diagnostics Market Dynamics – Factors Impact Analysis
3.6. Global Invitro Diagnostics Market – Regulations
3.6.1. U.S.
3.6.2. Europe
4. GLOBAL INVITRO DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL INVITRO DIAGNOSTICS MARKET , BY PRODUCT, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Reagents and consumables
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Instruments
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6. GLOBAL INVITRO DIAGNOSTICS MARKET FORECAST, BY TECHNIQUE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Immunochemistry
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Molecular diagnostics
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Clinical chemistry
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Tissue diagnostics
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Hemostasis and Coagulation
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Others
6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
7. GLOBAL INVITRO DIAGNOSTICS MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Cancer
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Infectious diseases
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Nephrological diseases
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Immune system disorders
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Gastrointestinal disorders
7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Neurological disorders
7.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.6.3. Market Opportunity Analysis
7.7. Hematological disorders
7.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.7.3. Market Opportunity Analysis
7.8. Others
7.8.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.8.3. Market Opportunity Analysis
8. GLOBAL INVITRO DIAGNOSTICS MARKET FORECAST, BY END-USER, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Hospitals
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Diagnostic Centres
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Point-of-care testing
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Others
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
9. GLOBAL INVITRO DIAGNOSTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. North America
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Invitro Diagnostics Market - Opportunity Analysis Index, By Product, By Technique, By Application, By End-User, and Region, 2017 – 2023
10. NORTH AMERICA INVITRO DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Reagents and consumables
10.1.2. Instruments
10.2. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Immunochemistry
10.2.2. Molecular diagnostics
10.2.3. Clinical chemistry
10.2.4. Tissue diagnostics
10.2.5. Hemostasis and Coagulation
10.2.6. Others
10.3. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Cancer
10.3.2. Infectious diseases
10.3.3. Nephrological diseases
10.3.4. Immune system disorders
10.3.5. Gastrointestinal disorders
10.3.6. Neurological disorders
10.3.7. Hematological disorders
10.3.8. Others
10.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospitals
10.4.2. Diagnostic Centres
10.4.3. Point-of-care testing
10.4.4. Others
10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Invitro Diagnostics Market - Opportunity Analysis Index, By Product, By Technique, By Application, By End-User, and Country, 2017 – 2023
10.7. North America Invitro Diagnostics Market Dynamics – Trends
11. EUROPE INVITRO DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Reagents and consumables
11.1.2. Instruments
11.2. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Immunochemistry
11.2.2. Molecular diagnostics
11.2.3. Clinical chemistry
11.2.4. Tissue diagnostics
11.2.5. Hemostasis and Coagulation
11.2.6. Others
11.3. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Cancer
11.3.2. Infectious diseases
11.3.3. Nephrological diseases
11.3.4. Immune system disorders
11.3.5. Gastrointestinal disorders
11.3.6. Neurological disorders
11.3.7. Hematological disorders
11.3.8. Others
11.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospitals
11.4.2. Diagnostic Centres
11.4.3. Point-of-care testing
11.4.4. Others
11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Invitro Diagnostics Market - Opportunity Analysis Index, By Product, By Technique, By Application, By End-User, and Country, 2017 – 2023
11.7. Europe Invitro Diagnostics Market Dynamics – Trends
12. ASIA-PACIFIC INVITRO DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Reagents and consumables
12.1.2. Instruments
12.2. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Immunochemistry
12.2.2. Molecular diagnostics
12.2.3. Clinical chemistry
12.2.4. Tissue diagnostics
12.2.5. Hemostasis and Coagulation
12.2.6. Others
12.3. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Cancer
12.3.2. Infectious diseases
12.3.3. Nephrological diseases
12.3.4. Immune system disorders
12.3.5. Gastrointestinal disorders
12.3.6. Neurological disorders
12.3.7. Hematological disorders
12.3.8. Others
12.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospitals
12.4.2. Diagnostic Centres
12.4.3. Point-of-care testing
12.4.4. Others
12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Invitro Diagnostics Market - Opportunity Analysis Index, By Product, By Technique, By Application, By End-User, and Country, 2017 – 2023
12.7. Asia- Pacific Invitro Diagnostics Market Dynamics – Trends
13. LATIN AMERICA INVITRO DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Reagents and consumables
13.1.2. Instruments
13.2. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Immunochemistry
13.2.2. Molecular diagnostics
13.2.3. Clinical chemistry
13.2.4. Tissue diagnostics
13.2.5. Hemostasis and Coagulation
13.2.6. Others
13.3. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Cancer
13.3.2. Infectious diseases
13.3.3. Nephrological diseases
13.3.4. Immune system disorders
13.3.5. Gastrointestinal disorders
13.3.6. Neurological disorders
13.3.7. Hematological disorders
13.3.8. Others
13.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospitals
13.4.2. Diagnostic Centres
13.4.3. Point-of-care testing
13.4.4. Others
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Venezuela
13.5.5. Rest of Latin America
13.6. Latin America Invitro Diagnostics Market - Opportunity Analysis Index, By Product, By Technique, By Application, By End-User, and Country, 2017 – 2023
13.7. Latin America Invitro Diagnostics Market Dynamics – Trends
14. MIDDLE EAST AND AFRICA INVITRO DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
14.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Reagents and consumables
14.1.2. Instruments
14.2. Technique Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Immunochemistry
14.2.2. Molecular diagnostics
14.2.3. Clinical chemistry
14.2.4. Tissue diagnostics
14.2.5. Hemostasis and Coagulation
14.2.6. Others
14.3. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Cancer
14.3.2. Infectious diseases
14.3.3. Nephrological diseases
14.3.4. Immune system disorders
14.3.5. Gastrointestinal disorders
14.3.6. Neurological disorders
14.3.7. Hematological disorders
14.3.8. Others
14.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospitals
14.4.2. Diagnostic Centres
14.4.3. Point-of-care testing
14.4.4. Others
14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Invitro Diagnostics Market - Opportunity Analysis Index, By Product, By Technique, By Application, By End-User, and Country, 2017 – 2023
14.7. MEA Invitro Diagnostics Market Dynamics – Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Becton, Dickinson and Company (U.S.)
15.2.2. Abbott Laboratories (U.S.)
15.2.3. Danaher Corporation (U.S.)
15.2.4. Roche Diagnostics (Switzerland)
15.2.5. Siemens Healthineers (Germany)
15.2.6. Thermo Fisher Scientific, Inc. (U.S.)
15.2.7. Sysmex Corporation (Japan)
15.2.8. bioMérieux (France)
15.2.9. Bio-Rad Laboratories, Inc. (U.S.)
15.2.10. Qiagen N.V. (Germany)
15.2.11. Diasorin S.P.A. (Italy)
15.2.12. Ortho-Clinical Diagnostics, Inc. (U.S.)
15.2.13. Johnson and Johnson (U.S.)
16. RESEARCH METHODOLOGY
17. KEY ASSUMPTIONS AND ACRONYMS
